louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05661864: Multi-Tiered Systems of Support for Teacher Training in Classroom Management
Official title: Multi-Tiered Systems of Teacher Training and Classroom Management
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Universal Behavioral Supports
Teacher Training
Lead sponsor: Western Kentucky University
Sponsor class: OTHER
First posted: 2022-12-22
Enrollment: 70
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Participants are randomly assigned to one of two groups. Both groups receive intervention, but to different classroom management strategies.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to test the effects of a responsive approach to training teachers to increase their use of evidence-based classroom management practices. The main question to answer is whether teachers increase their use of a target classroom management practice when they receive the intervention. All participants will receive the intervention. The target practice for which they receive intervention will be randomly assigned. Participants will submit videos of an instructional activity in their classroom 1-2 times per week over a period of 12-15 weeks. They will be asked to complete online modules on classroom management practices and to self-monitor their use of one classroom management practice. Participants may also be asked to graph their data, watch videos of themselves teaching, or implement peer coaching with a classmate or other participant. Researchers will compare the change in target classroom management practices between groups to test if the change in the group who targeted the practice is greater than the change in the group who did not target the practice.


Eligibility criteria: Inclusion Criteria:

* Enrolled in EDU 502 or PK-12 classroom teacher

Exclusion Criteria:

* Inability to submit video recordings of instruction for data collection and analysis

Primary outcomes:
measure: Change in the frequency of the target practice
timeFrame: Baseline, endpoint (15 weeks from start date)
Secondary outcomes:
Other outcomes:
Locations:
city: Bowling Green
country: United States
facility: Western Kentucky University
state: Kentucky
Study officials:
References:
Clinical trial NCT01595464: Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza
Official title: A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Posttraumatic Stress Disorder
Lead sponsor: The Center for Mind-Body Medicine
Sponsor class: OTHER
Collaborators: name: The Atlantic Philanthropies
First posted: 2012-05-10
Enrollment: 148
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to determine whether participation in a mind-body skills program by war-traumatized adults in Gaza will result in improvement of posttraumatic stress symptoms and depression, and will increase posttraumatic growth compared to a control group.


Eligibility criteria: Inclusion Criteria:

* having experienced a political violence or war-related criterion A stressor
* meeting the American Psychiatric Association (DSM-IV TR) criteria for PTSD according to screening scores on the PTSD Checklist- Civilian version

Exclusion Criteria:

* former psychosocial or medical treatment for mental health conditions
* significant cognitive impairment

Primary outcomes:
measure: PTSD Checklist-Civilian Version
timeFrame: Change from Baseline (Week 1) at 11 weeks
measure: PTSD Checklist-Civilian Version
timeFrame: Change from Week 11 at 23 weeks
measure: PTSD Checklist-Civilian Version
timeFrame: Change from Baseline (Week1) at 23 Weeks
Secondary outcomes:
measure: Center for Epidemiological Studies Depression Scale (CES-D)
timeFrame: Change from Baseline (Week 1) at 11 weeks
measure: Center for Epidemiological Studies Depression Scale (CES-D)
timeFrame: Change from Week 11 at 23 weeks
measure: Center for Epidemiological Studies Depression Scale (CES-D)
timeFrame: Change from Baseline (Week1) at 23 Weeks
measure: Posttraumatic Growth Inventory
timeFrame: Change from Baseline (Week 1) at 11 weeks
measure: Posttraumatic Growth Inventory
timeFrame: Change from Week 11 at 23 weeks
measure: Posttraumatic Growth Inventory
timeFrame: Change from Baseline (Week1) at 23 Weeks
Other outcomes:
Locations:
city: Gaza City
country: Israel
facility: The Center for Mind-Body Medicine
state: Palestine
Study officials:
affiliation: The Center for Mind-Body Medicine
name: James S Gordon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06733064: Strenght Training in Osteoporosis Prevention
Official title: Effective Prevention of Osteoporosis Through Rehabilitation and Training
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Osteopenia or Osteoporosis
Keywords: strenght training
vitamin d3
osteoporosis
osteopenia
Lead sponsor: University of Gdansk
Sponsor class: OTHER
First posted: 2024-12-13
Enrollment: 120
Sex: FEMALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study involves 120 women over the age of 50.

All participants in the study take part in high-intensity strength training for 10 months.

In addition, half of the participants receive vitamin D3 at a dose of 4,000 IU/day.

The investigators hypothesize that training combined with vitamin D3 supplementation will be more effective in preventing osteoporosis than training alone.


Eligibility criteria: Inclusion Criteria:

* age over 50
* female

Exclusion Criteria:

* ongoing cancer,
* unstabilized cardiovascular disease,
* cognitive disorders,
* radiological treatment in the last 12 months,
* other contraindications to undertaking high-intensity strength training,
* diseases affecting the skeleton such as: Paget's disease, type I diabetes mellitus,
* taking medications affecting skeletal conditions including: long-term therapy with corticosteroids, thiazides, antiretroviral drugs,
* contraindications to taking vitamin D including: hypercalcemia, nephrolithiasis, sarcoidosis, lack of cholecalciferol hydroxylase activity in the liver and kidneys.

Primary outcomes:
measure: Bone Mineral Density
timeFrame: Measured at 3 time points: before the experiment, after 10 months of training, and at 6 months after the end of training and supplementation.
Secondary outcomes:
measure: Vitamin D metabolites level
timeFrame: Measured at 4 time points: before the experiment, after 5 and 10 months of training, and at 6 months after the end of training and supplementation.
Other outcomes:
Locations:
city: Gdańsk
country: Poland
facility: University of Gdańsk, Faculty of Biology
state: Pomorskie
city: Gdańsk
country: Poland
facility: University of Gdańsk, Faculty of Biology
Study officials:
affiliation: University of Gdansk
name: Mateusz Karnia, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06565364: Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients
Official title: Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombocytopenia
Antibodies Drug Specific
Keywords: Thrombin generation
Protamine
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 160 patients were included to the study with written informed consent. 4 patients did not undergo the planned surgical procedure due to medical reasons and therefore had to be excluded subsequently.

Brief summary: The primary aim of this study was to describe the prevalence and time course of the occurrence of protamine/heparin antibodies in patients undergoing cardiac surgery on cardiopulmonary bypass.

The second aim was to identify triggers of immunization.

The third aim of this study was to evaluate a potential clinical impact of protamine/heparin antibodies and their platelet-activating properties leading to thromboembolism and other adverse outcomes.


Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years
* cardiac surgery on cardiopulmonary bypass

Exclusion Criteria:

* cardiac surgery without cardiopulmonary bypass
* age \< 18 years
* no written consent

Primary outcomes:
measure: prevalence of protamine/heparin antibodies
timeFrame: preoperatively until postoperative day 10
Secondary outcomes:
measure: Potential triggers
timeFrame: preoperatively
measure: Clinical impact
timeFrame: until postoperative day 10
Other outcomes:
measure: Thrombin generation
timeFrame: preoperatively until postoperative day 6
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
Study officials:
affiliation: Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna
name: Barbara Steinlechner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01384864: Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia
Official title: Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Barrett's Esophagus
Intraepithelial Neoplasia
Keywords: barrett's esophagus
intraepithelial neoplasia
cross polarized reflectance examination
vital-dye enhanced fluorescence examination
Lead sponsor: Anandasabapathy, Sharmila, M.D.
Sponsor class: INDIV
Collaborators: name: William Marsh Rice University
First posted: 2011-06-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The overall objective of this pilot study is to determine whether multispectral imaging increases the diagnostic accuracy of the current standard of high-definition white-light endoscopy for the detection of Barrett's-associated neoplasia (high grade dysplasia or cancer). The investigators goal is to develop a multispectral endoscopic platform that can be used to survey a large surface area and, potentially, serve as a 'red flag' for microendoscopic imaging of small areas. The goal of this pilot study is to preliminarily determine the accuracy of these modalities during the endoscopic surveillance of Barrett's esophagus.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* known or suspected barrett's esophagus with intraepithelial neoplasia(HGD/cancer)

Exclusion Criteria:

-

Primary outcomes:
measure: to determine whether tissue is neoplastic or non-neoplastic
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
Study officials:
References:
Clinical trial NCT02027064: Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Acute Myeloid Leukemia
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2014-01-03
Enrollment: 40
Sex: ALL
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.

Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.

the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)


Eligibility criteria: Inclusion Criteria:

* high risk t (8; 21) AML
* molecular relapse after allo-SCT

Exclusion Criteria:

* active graft-versus-host disease
* uncontrolled severe infection
* organ function failure

Primary outcomes:
measure: relapse rate
timeFrame: participants will be followed for an expected average of 365 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
Study officials:
References:
citation: Shen MZ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YH, Han W, Wang FR, Wang JZ, Zhao XS, Qin YZ, Chang YJ, Liu KY, Huang XJ, Mo XD. Preemptive Interferon-alpha Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Front Immunol. 2022 Jan 28;13:757002. doi: 10.3389/fimmu.2022.757002. eCollection 2022.
citation: Mo XD, Wang Y, Zhang XH, Xu LP, Yan CH, Chen H, Chen YH, Qin YZ, Liu KY, Huang XJ. Interferon-alpha Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist. 2018 Nov;23(11):1349-1357. doi: 10.1634/theoncologist.2017-0692. Epub 2018 Aug 3.
Clinical trial NCT00013364: Effects of Stimulus Validity on Speech Recognition
Official title: Effects of Stimulus Validity on Speech Recognition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hearing Impaired
Keywords: Hearing loss, speech recognition
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-03-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The effects of talker variability will be investigated with four groups of listeners (young normal-hearing; old normal-hearing; young hearing-impaired; old hearing-impaired). Experimental conditions will include between-talker differences, speaking rate, lexical difficult and semantic/linguistic context. A preliminary experiment will evaluate the relative merit of adaptive vs fixed-level methods of stimulus presentation.


Eligibility criteria: Hearing impaired

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: VAMC, West Los Angeles
state: California
Study officials:
affiliation: Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service
name: John Fryer, Ph.D., Program Analyst
affiliation: Program Analysis and Review Section (PARS), Rehabilitation Research & Development Service
name: Nancy Roceleau, Program Analyst
References:
Clinical trial NCT03393364: Pain Management in Outpatient Urologic Procedures
Official title: Pain Management in Outpatient Urologic Procedures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Urologic Diseases
Lead sponsor: University Hospitals Cleveland Medical Center
Sponsor class: OTHER
First posted: 2018-01-08
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Goal of this study is to evaluate how pain is controlled after outpatient urologic surgeries. Patients will receive either opioid pain medication or non-opioid medication for pain control. A survey will be conducted at the post-operative appointment to evaluate for pain control.

Detailed description: Patients will be approached in the pre-operative area prior to their outpatient urologic surgery. Informed Consent will be obtained at that time. Patients will be instructed that they will receive a prescription for either opioid pain medication or non-opioid medication for after surgery. The opioid medication includes oxycodone, while the non-opioid includes ketoralac, a non-steroidal anti-inflammatory medication. Subjects will be assigned randomly to either medication. Standard of care after outpatient urologic surgery is either oxycodone or ketoralac, however there is no previous research on whether one is superior than the other. These drugs were chosen because they are the most commonly used medications after outpatient urologic surgery. The study team and patients will not be blinded to the treatment.

They will also receive instructions for non-opioid pain management. If the patients require additional pain medication after surgery, they are instructed to call the provider's office for further evaluation and treatment. The patient's physician will prescribe further medication if warranted. The post-operative appointment is scheduled 2-3 weeks after surgery. At the post-operative appointment, patients will then be given a four question paper survey inquiring how well their pain was managed, how many pills were taken, if any additional non-opioid medications were taken for pain, and how the extra pills were disposed. Other PHI that will be collected includes patient's age, gender, past medical history, past surgical history, renal function, prior medications, and current surgery.

Eligibility criteria: Inclusion Criteria:

* outpatient urologic surgery
* age 18 and over

Exclusion Criteria:

* renal dysfunction
* non-English speaking
* employees of organization

Primary outcomes:
measure: Pain control
timeFrame: within 6 weeks of surgery
Secondary outcomes:
measure: Number of pills used
timeFrame: within 6 weeks of surgery
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: University Hospitals
state: Ohio
Study officials:
affiliation: University Hospitals Cleveland Medical Center
name: Lee Ponsky, MD, MBA
role: STUDY_CHAIR
References:
Clinical trial NCT01850264: Quartet™ Bad Oeynhausen Trial
Official title: Quartet™ Bad Oeynhausen Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Congestive Heart Failure
Cardiac Resynchronization Therapy
Keywords: cardiac resynchronization therapy; heart failure, congestive
Lead sponsor: Heart and Diabetes Center North-Rhine Westfalia
Sponsor class: OTHER
First posted: 2013-05-09
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective of this study is to evaluate whether the use of a quadripolar left ventricular (LV) electrode compared to a standard bipolar LV electrode leads to lower non-responder rates in patients undergoing cardiac resynchronization therapy (CRT)


Eligibility criteria: Inclusion Criteria:

* Indication for CRT-D implantation according to current guidelines
* Ischemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM)
* Sinus rhythm
* NYHA II-IV
* Age ≥ 18 years
* Written informed consent to participate in the study

Exclusion Criteria:

* Right bundle brunch block
* Valvular cardiomyopathy
* Patient receiving a non-transvenous LV electrode
* Known pregnancy
* Age \< 18 years
* Life expectancy \< 1 year
* Atrial fibrillation / atrial flutter at the time of enrolment
* Inability to provide informed consent
* Participation in another study with active therapeutic arm
* Regular follow-up in the study center within the first 6 months after implantation not guaranteed

Primary outcomes:
measure: Increase in peak oxygen consumption
timeFrame: 6 months
measure: Reduction of New York Heart Association (NYHA) functional class
timeFrame: 6 months
measure: Survival
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bad Oeynhausen
country: Germany
facility: Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum
Study officials:
affiliation: Heart and Diabetes Center North Rhine-Westphalia, Department of Cardiology
name: Klaus-Juergen Gutleben, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05925764: WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
Official title: Whole Slide Image Based Deep Learning for Diagnosing the International Association for the Study of Lung Cancer Proposed Grading System of Lung Adenocarcinoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lung Adenocarcinoma
Whole Slide Image
IASLC Grading System
Artificial Intelligence
Lead sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Sponsor class: OTHER
First posted: 2023-06-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Resected Lung Adenocarcinoma

Brief summary: The purpose of this study is to evaluate the performance of a whole slide image based deep learning model for diagnosing the IASLC grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.


Eligibility criteria: Inclusion Criteria:

1. Age ranging from 18-85 years old;
2. Pathological confirmation of primary lung adenocarcinoma after surgery;
3. Obtained written informed consent.

Exclusion Criteria:

1. Multiple lung lesions;
2. Poor quality of whole slide images;
3. Mucinous adenocarcinomas and variants;
4. Participants who have received neoadjuvant therapy.

Primary outcomes:
measure: Agreement rate of the IASLC grading system
timeFrame: 2024.11.01-2024.12.31
Secondary outcomes:
measure: Agreement rate of the predominant subtypes
timeFrame: 2024.11.01-2024.12.31
Other outcomes:
Locations:
city: Zunyi
country: China
facility: Affiliated Hospital of Zunyi Medical University
state: Guizhou
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
state: Jiangxi
city: Ningbo
country: China
facility: Ningbo HwaMei Hospital
state: Zhejiang
Study officials:
References: